TCI Wealth Advisors Inc. increased its stake in shares of Baxter International Inc (NYSE:BAX) by 19.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,700 shares of the medical instruments supplier’s stock after buying an additional 446 shares during the period. TCI Wealth Advisors Inc.’s holdings in Baxter International were worth $226,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the stock. Horrell Capital Management Inc. boosted its stake in shares of Baxter International by 0.4% in the 4th quarter. Horrell Capital Management Inc. now owns 30,990 shares of the medical instruments supplier’s stock valued at $2,591,000 after purchasing an additional 114 shares during the last quarter. Schmidt P J Investment Management Inc. lifted its position in Baxter International by 4.2% during the third quarter. Schmidt P J Investment Management Inc. now owns 3,095 shares of the medical instruments supplier’s stock valued at $271,000 after purchasing an additional 125 shares during the last quarter. Dubuque Bank & Trust Co. raised its stake in shares of Baxter International by 4.1% during the fourth quarter. Dubuque Bank & Trust Co. now owns 4,925 shares of the medical instruments supplier’s stock worth $412,000 after acquiring an additional 195 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Baxter International by 2.9% during the third quarter. Parallel Advisors LLC now owns 6,994 shares of the medical instruments supplier’s stock worth $612,000 after acquiring an additional 196 shares in the last quarter. Finally, Coastline Trust Co raised its stake in shares of Baxter International by 0.6% during the fourth quarter. Coastline Trust Co now owns 32,762 shares of the medical instruments supplier’s stock worth $2,739,000 after acquiring an additional 198 shares in the last quarter. 82.56% of the stock is owned by institutional investors and hedge funds.
NYSE BAX opened at $89.61 on Monday. The company has a 50-day moving average price of $85.57 and a 200-day moving average price of $84.64. The firm has a market capitalization of $46.35 billion, a P/E ratio of 30.17, a PEG ratio of 2.11 and a beta of 0.98. Baxter International Inc has a 52 week low of $69.86 and a 52 week high of $91.86. The company has a quick ratio of 2.10, a current ratio of 2.78 and a debt-to-equity ratio of 0.72.
Several research analysts have commented on BAX shares. Morgan Stanley raised shares of Baxter International from an “equal weight” rating to an “overweight” rating in a research note on Thursday, January 2nd. UBS Group restated a “buy” rating and set a $102.00 target price on shares of Baxter International in a report on Monday, January 13th. JPMorgan Chase & Co. boosted their target price on shares of Baxter International from $89.00 to $94.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Evercore ISI upgraded shares of Baxter International from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $80.00 to $94.00 in a research note on Thursday, January 2nd. Finally, Deutsche Bank started coverage on shares of Baxter International in a research note on Monday, October 21st. They issued a “buy” rating and a $109.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $92.64.
In related news, Director John D. Forsyth sold 1,500 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $83.64, for a total value of $125,460.00. Following the completion of the sale, the director now directly owns 30,078 shares of the company’s stock, valued at approximately $2,515,723.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.70% of the company’s stock.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: Debt-To-Equity Ratio
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.